Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageJornay PM is a central nervous system (“CNS”) stimulant prescription medicine that contains methylphenidate HCl, a Schedule II methylphenidate, which was approved by the U.S. Food and Drug Administration (“FDA”) in August 2018 for the treatment of ADHD in people six years of age and older and currently the only FDA-approved stimulant medication that is dosed in the evening.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Jun 2026 · $199.9MThe company’s own SEC segment disclosure.
- Belbuca$57.7M29%
- Jornay Pm$46.1M23%
- Xtampza ER$45.0M23%
- Nucynta ER$15.7M8%
- Nucynta IR$14.4M7%
- Azstarys$12.9M6%
- Other (3)$8.2M4%
Collegium Pharmaceutical, Inc. (COLL) reported revenue of $194M in Q1 2026 (quarter ended Mar 31, 2026), up 8.9% from the same quarter a year earlier. That came with a gross margin of 61% and net income of $14M (7.5% of revenue). For the full year FY2025, revenue was $781M (+24% year on year) and net income $63M. Its largest product in Jun 2026 was Belbuca at $58M, 29% of the disclosed total, just ahead of Jornay Pm at 23%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #16 of 29 by Smart Score